our equipment matches our dedication
We are committed to providing our patients with the best treatment possible. That not only means having a highly-skilled and experienced staff, but also utilizing industry-leading equipment.
At SFPTI, we use the TrueBeam® radiotherapy system by Varian to administer radiation treatment. The TrueBeam® is an advanced medical linear accelerator (Linac) that is fully integrated for image-guided radiotherapy and radiosurgery, and is designed to treat tumors with tremendous speed and accuracy.
TrueBeam® is able to treat cancer anywhere in the body. With the ability to treat quickly while also delivering highly-precise dose rates, TrueBeam® has become a preferred system among radiation oncologists.
TrueBeam® is capable of delivering a wide spectrum of advanced treatment modalities including intensity modulated radiation therapy (IMRT); stereotactic body radiotherapy (SBRT); and RapidArc® radiotherapy, a form of volumetric modulated arc therapy (VMAT); high-precision Stereotactic Radiosurgery with HyperArcTM; improved soft-tissue visualization via iterative Cone-Beam CT (iCBCT); and enhancements to intrafraction motion management techniques that ensure treatments are delivered exactly as planned.
At SFPTI, we use the Edge® Radiosurgery System from Varian, which allows our team to track a patient’s tumor in real time, precisely calculate patient movement in all six degrees of freedom, and monitor respiratory motion. By integrating the highest dose rate (2400 MU per minute) with non-ionizing, direct and real-time guidance for target location, the Edge® makes it possible to pinpoint the target and deliver highly focused treatments in fewer sessions and at a noticeably faster rate, while minimizing the dose received by surrounding healthy tissues.
The ability to accurately deliver targeted treatments and manage tumor motion is driving growth in Stereotactic Radiosurgery (SRS). A 108% increase in SRS utilization for brain cancer treatments is predicted over the next 10 years, and SRS treatment volume is expected to grow 93% and Stereotactic Body Radiation Therapy (SBRT) volume is expected to grow 144% within that span.
Using technology designed for radiosurgical ablation, the Edge® represents an evolution in the way advanced radiosurgery is delivered and cancer is treated.